the ergogenic effect of recombinant human erythropoietin on v？o2max depends on the severity of arterial hypoxemia重组人红细胞生成素的生力的影响v o2max取决于动脉低氧血症的严重程度.pdf

The Ergogenic Effect of Recombinant Human ˙ Erythropoietin on VO2max Depends on the Severity of Arterial Hypoxemia 1,7 2,4 2 6 7 Paul Robach *, Jose A. L. Calbet , Jonas J. Thomsen , Robert Boushel , Pascal Mollard , Peter Rasmussen2,3, Carsten Lundby2,5 1 Ecole Nationale de Ski et d’Alpinisme, Chamonix, France, 2 The Copenhagen Muscle Research Centre, Rigshospitalet, Copenhagen, Denmark, 3 Department of Anaesthesia, Rigshospitalet, Copenhagen, Denmark, 4 Department of Physical Education, University of Las Palmas de Gran Canaria, Las Palmas, Spain, 5 Department of ˚ ˚ ´ Sport Science, University of Arhus, Arhus, Denmark, 6 Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, 7 Laboratoire ‘‘Reponses ` ´ cellulaires et fonctionnelles a l’hypoxie’’, EA 2363, A.R.P.E., Universite Paris 13, Bobigny, France Abstract Treatment with recombinant human erythropoietin (rhEpo) induces a rise in blood oxygen-carrying capacity (CaO ) that 2 ˙ unequivocally enhances maximal oxygen uptake (VO max) during exercise in normoxia, but not when exercise is carried out